| Value | ₹20.00 Cr |
|---|
NSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹734.95
- Market cap
- ₹11,568 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 31.8×Sector 43.0×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.
- Value
- ₹680.0 Cr
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Other adverse business impact announcements
All →GRE Renew Enertech Adverse Business Impact
GRE Renew Enertech received Urjasol Energy's request to cancel a solar EPC purchase order. The company acknowledged the cancellation on 7 November 2026.
- From
- Urjasol Energy Private Limited
Aster DM Quality Care Adverse Business Impact
Aster DM Quality Care terminated its O&M and Medical Services agreements with DM Education and Research Foundation, ceasing related hospital operations. The Aster Wayanad hospital contributed 1.20% of turnover; no consideration was received.
Andhra Sugars Adverse Business Impact
The Andhra Sugars closed its Bhimadole sugar unit and Kovvur sulphuric acid unit, effective 1 October 2026. Board approved closures on 7 November 2026, citing plant age and cane unavailability.
Lancer Container Lines Adverse Business Impact
Lancer Container Lines disclosed a cyber fraud at its wholly owned UAE subsidiary, Lancia Shipping LLC. The estimated impact is USD 100,000, about Rs.0.94 Crore.
- Value
- ₹0.94 Cr
Oil India Adverse Business Impact
Oil India reported a fire at an Indirect Bath Heater at its ITF-Tengakhat facility on 6 November 2026. One O&M contractor worker died and six were injured, and the fire was extinguished by 12:30 PM.
Goa Carbon Adverse Business Impact
Goa Carbon temporarily shut its Bilaspur unit from 6 November 2026 for maintenance work. The shutdown may temporarily affect production at the plant.
- Execution
- Temporary shutdown from 6 November 2026, duration not stated